<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624320</url>
  </required_header>
  <id_info>
    <org_study_id>Gordon Schanzlin New Vision</org_study_id>
    <nct_id>NCT05624320</nct_id>
  </id_info>
  <brief_title>Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses</brief_title>
  <official_title>Improved Near Vision and Intermediate Without Loss of Binocular Distance Vision Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses for Distance Vision Correction in Both Eyes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gordon Schanzlin New Vision</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gordon Schanzlin New Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      AGN-190584 has gone through many clinical trials showing its safety and effectiveness in&#xD;
      individuals from 40-55 years of age. There has been no published data on the use of this&#xD;
      product in individuals corrected with contact lenses for distance vision. There are many&#xD;
      other applications AGN-190584 could be used for and further studies will show the&#xD;
      effectiveness for each.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a single center open label, single arm study with no control and no&#xD;
      randomization. Investigators will enroll 30 presbyopic patients between the ages of 40-55&#xD;
      years old who have undergone successful contact lens fitting in single-use, daily, contact&#xD;
      lenses between the spectacle lens powers of -4.00 -to +1.00, in both eyes for best distance&#xD;
      correction by the primary investigator. Investigators will measure change in letters read at&#xD;
      near and intermediate vision from baseline. Subjects will be required to apply AGN-190584&#xD;
      drops once daily OU. Subjects will be applying the drops on their own every day including the&#xD;
      day of visits. During treatment investigators will measure changes in letters read from&#xD;
      baseline in intermediate and near vision at the days 7, 14 and 21. These visits will be&#xD;
      conducted between 2 and 4 hours after instillation of AGN-190584, with 3 hours being the&#xD;
      target time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint will be changes from baseline in letters read at near without loss of distance acuity (defined as loss of 5 or more letters)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>secondary endpoint will be changes in intermediate letters read from baseline</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>single center open label, single arm study with no control and no randomization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigators will enroll 30 presbyopic patients between the ages of 40-55 years old who have undergone successful contact lens fitting in single-use, daily, contact lenses between the spectacle lens powers of -4.00 -to +1.00, in both eyes for best distance correction by the primary investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-190584</intervention_name>
    <description>miotic for treatment of presbyopia</description>
    <arm_group_label>single center open label, single arm study with no control and no randomization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects from age 40-55&#xD;
&#xD;
          -  Prescription range: -4.00 - +1.00&#xD;
&#xD;
          -  Correctable to 20/25 or better for distance&#xD;
&#xD;
          -  Adapted single use contact lens patients&#xD;
&#xD;
          -  Subjects able to understand the consent agreement and willing to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-contact lens wearer&#xD;
&#xD;
          -  Previous use of AGN-190584&#xD;
&#xD;
          -  Out of age range&#xD;
&#xD;
          -  Out of prescription range&#xD;
&#xD;
          -  Any corneal abnormality&#xD;
&#xD;
          -  Any eye pathology&#xD;
&#xD;
          -  Iritis&#xD;
&#xD;
          -  Know allergy to pilocarpine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David I Geffen, OD</last_name>
    <phone>18584559950</phone>
    <email>dgeffen@gwsvision.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Garret Pennel, OD</last_name>
    <phone>(858) 455-6800</phone>
    <email>gpennel@gwsvision.com</email>
  </overall_contact_backup>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>November 21, 2022</last_update_submitted>
  <last_update_submitted_qc>November 21, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>presbyopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

